Nymox Pharmaceutical Corp

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert, TobacAlert and Fexapotide Triflutate for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.

IRVINE Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that the Company's stock has resumed trading under the symbol NYMXF on the Over the Counter QB (OTCQB®) Venture Market. This is a higher level tier from the Company's prior listing. With the new OTCQB listing, Nymox's stock is now eligible for proprietary broker-dealer quotations.

NYMOX Announces Trading Resumed and New Listing on OTCQB Market

IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) is pleased to report that it filed its Annual Report with the Security and Exchange Commission (SEC) on August 29, 2024.

Nymox Announces Filing of Annual Report

IRVINE, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that its Annual Report is and has been in progress since late February, soon after Nymox received some of its corporate documents withheld by the terminated officers and directors. Unfortunately, this has caused delays beyond the Company's control in its completion. The Company believes that the audit will be completed soon, and it will issue its annual report as soon as possible thereafter.

Nymox Annual Report

IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that its MAA submission to the Danish Medicines Agency (DKMA) has run out of time and in order to continue will be required to extend the MAA application to DKMA by re-submission with a new fee required. As it currently stands the application “does not meet the conditions of the Medicines Act for issuing a marketing authorization.” Although a great number of questions were resolved by the Company, there remain further responses required that will require additional cycle time. The Company is busy analyzing the approaches that are possible. Nymox cannot guarantee that all questions can be resolved. The Company believes that it has the data required to formulate the required re-submission.

Nymox Required to Resubmit Application to DKMA

IRVINE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets - NYMXF) is pleased to report that the Bahamas Supreme Court has issued a formal Order officially putting an end to the Bahamas litigation brought by terminated ex-employees. The Order also awards to Nymox its costs incurred in defending the ill-conceived lawsuit, as well as damages Nymox has suffered as a result of the litigation.

Nymox Reports Victory in Bahamas Litigation Against Terminated Ex-Employees – Court Awards Costs and Damages

IRVINE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) is pleased to provide this end-of-the year message to shareholders.

Nymox December 27 Message to Shareholders

IRVINE, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that the California Superior Court, Orange County (OCSC) has issued an order granting Nymox's preliminary injunction against Randall Lanham, Richard Cutler, Christopher Riley, and the Committee to Restore Nymox Shareholder Value.

Nymox Reports California Court Issues Preliminary Injunction Against Defendants Lanham, Riley, Cutler and Others

IRVINE, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that the California Superior Court, Orange County (OCSC) has accepted on November 18, 2023 Nymox's lawsuit against AscellaHealth and issued a Summons to be served on Ascella. The lawsuit is styled Nymox Pharmaceutical Corporation vs. AscellaHealth, LLC., case No. 30-2023-01362136-CU-BT-CJ. Nymox filed its lawsuit in California Superior Court, Orange County on November 8, 2023, to protect its shareholders' interests, as Nymox alleges that AscellaHealth, LLC (“Ascella”) engaged in unlawful means in repeated attempts to gain control of Nymox for its own advantage, at what would have been at the expense of Nymox's shareholders.

$250 Million Lawsuit Filed Against AscellaHealth by Nymox Accepted and Summons Issued in California Court

IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- This week, Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets - NYMXF) was forced to file a lawsuit in California Superior Court, Orange County, to protect its shareholders' interests, as Nymox alleges that a would-be “black knight” competitor resorted to illegal and unlawful corporate espionage because it could not garner the support of enough Nymox shareholders by legitimate means. This company is Defendant AscellaHealth, LLC (“Ascella”). Unlike even a contentious hostile takeover bid, Ascella engaged in unlawful means in repeated attempts to gain control of Nymox for its own advantage, at what would have been the expense of Nymox's shareholders.

Nymox Pharmaceutical Corporation Sues AscellaHealth For $250 Million

IRVINE, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox” or the “Company”) [OTC Markets---NYMXF] is pleased to announce that the Bahamian Court (Senior Justice Deborah Fraser) today issued an oral ruling suspending the Ex Parte Order of October 3, 2023 wrongly obtained by the so called activist shareholders led by Mr. Lanham. Senior Justice Fraser accepted Nymox's arguments that justice would best be served with the order suspended.

NYMOX REPORTS: Bahamian Court Today Suspends Order of October 3, 2023 Rendering Riley-Lanham and Accomplices Planned Vote Unauthorized

Ex-Employees and Agents, and those working in concert with them, are ordered by a California Court to stop using, disclosing, relying on, or otherwise make publicly available Nymox privileged information, and to return all Nymox material to the Company

NYMOX REPORTS NOTICE: California Court Issued A Temporary Restraining Order Enjoining Lanham, Riley, Cutler And Their Nevada Company After Court Hearing In Santa Ana, California, November 2, 2023

IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- The following is Nymox's response to an unauthorized shareholder meeting: Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company” or “Nymox”) warns its shareholders that false and manipulative behavior is involved in attempts to hold what the Company considers an unlawful, unauthorized, and improper "shareholders meeting" that does not have the support of the Company or anyone currently associated with the Company.

IMPORTANT MESSAGE TO NYMOX SHAREHOLDERS: NYMOX Cautions Against Unauthorized Improper Shareholder Meeting and Unauthorized Unregistered Solicitations

IRVINE Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- The following is Nymox's response to an unauthorized shareholder meeting: Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company” or “Nymox”) warns its shareholders that false and manipulative behavior is involved in attempts to hold what the Company believes is an unlawful, unauthorized, and improper "shareholders meeting" that does not have the support of the Company or anyone currently associated with the Company.

IMPORTANT NOTICE: NYMOX Cautions Shareholders Not to Take Calls or Participate in Unauthorized Improper Shareholder Meeting

IRVINE, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- The following is Nymox's response to an unauthorized shareholder meeting: Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) warns its shareholders that false and manipulative behavior is involved in attempts to hold an unlawful, unauthorized, and improper "shareholders meeting" that does not have the support of the Company or anyone currently associated with the Company.

Notice: Nymox Informs Its Shareholders Not to Take Calls or Participate in An Unauthorized and Improper Shareholder Meeting

IRVINE, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce that the Company's recent submission of Fexapotide Triflutate for the treatment of symptoms of benign prostate enlargement (benign prostatic hyperplasia, referred to as BPH) has been validated by the U.K. authorities, at U.K. Medicines & Healthcare products Regulatory Agency (MHRA). The formal review process has now started. The trademarked name for the new product is NYMOZARFEX (TM). The Marketing Authorization Application (MAA) was submitted September 25, 2023. The new submission includes England, Wales, Scotland and Northern Ireland. The Company will continue to provide further information, including other expected submissions, when the information becomes available.

Nymox Reports New NYMOZARFEX Marketing Application is Accepted For Review

Nymox Pharmaceutical

CARSON CITY, Nev. & LONDON--(BUSINESS WIRE)--THE COMMITTEE TO RESTORE NYMOX SHAREHOLDER VALUE SENDS LETTER TO NYMOX PHARMACEUTICAL SHAREHOLDERS.

The Committee to Restore Nymox Shareholder Value Sends Letter to Nymox Pharmaceutical Shareholders and Issues Proxy Materials for Upcoming Special Meeting

IRVINE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce today that a new formal submission has been made by the Company in the U.K. for Nymozarfex (TM) for the treatment of benign prostatic hyperplasia (BPH). The Marketing Authorization Application (MAA) was submitted to the U.K. Medicines & Healthcare products Regulatory Agency (MHRA). The new submission includes England, Wales, Scotland and Northern Ireland.

Nymox Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH

IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the completion of its recently reported private placement of USD 2 million. This new funding was undertaken for general corporate purposes and was priced at USD 1.00 per share. The investment was provided by long-term shareholder and distinguished Nymox Board member James Robinson.

Nymox Reports Completion of $2 Million Private Placement

IRVINE, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce an investment of US $2.0 million for 2 million shares at the price of $1.00 per share with 500,000 warrants priced at $2.00. The investment comes from James Robinson, a long-term shareholder of Nymox and a distinguished member of the Board of Directors of the Company. The funds will be used for general corporate purposes. The investment will close in the upcoming days after the customary formalities are completed.

Nymox Announces $2 Million Private Placement

Ex-CFO Provided to Nymox Before Appointment as CFO a Personal Resume with False Claim of Securing USD 62.5 million at his Previous Company Ex-CFO Provided to Nymox Before Appointment as CFO a Personal Resume with False Claim of Securing USD 62.5 million at his Previous Company

Nymox's 3-month ex-CFO was Awarded an Unauthorized and Undisclosed Treasury Directive for 100,000 Shares of Nymox Stock Without the Knowledge or Approval of the Nymox Board or Nymox's CEO

News for Nymox Pharmaceutical Corp Stock (NYMXF)